| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/22/2009 | EP2050762A2 Novel polypeptides and nucleic acids encoding the same |
| 04/22/2009 | EP2050466A1 Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
| 04/22/2009 | EP2050465A2 Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient |
| 04/22/2009 | EP2050464A2 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| 04/22/2009 | EP2050463A2 Vaccine compositon for vaccinating dogs against canine infectious respiratory disease (CIRD) |
| 04/22/2009 | EP2050335A1 Gene disruptions, compositions and methods relating thereto |
| 04/22/2009 | EP2049899A2 Methods to prevent and treat diseases |
| 04/22/2009 | EP2049893A2 Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
| 04/22/2009 | EP2049571A2 Targeted binding agents directed to pdgfr-alpha and uses thereof |
| 04/22/2009 | EP2049569A2 Hemagglutinin polypeptides, and reagents and methods relating thereto |
| 04/22/2009 | EP2049560A1 Process for preparing particles of proteinaceous material |
| 04/22/2009 | EP2049156A2 Compositions and methods for macular degeneration |
| 04/22/2009 | EP2049155A2 Antitumor combinations containing taxane derivatives |
| 04/22/2009 | EP2049154A1 Plasmids with immunological action |
| 04/22/2009 | EP2049153A1 Attenuated polio viruses |
| 04/22/2009 | EP2049152A2 Antibodies for norovirus |
| 04/22/2009 | EP2049141A1 Treatment for intimal hyperplasia and related conditions |
| 04/22/2009 | EP2048954A2 An isolated dna fragment of the sparc human promoter and its use |
| 04/22/2009 | EP1641819B1 Purification of her-2 variants |
| 04/22/2009 | EP1468014B1 Compositions and methods for WT1 specific immunotherapy |
| 04/22/2009 | EP1466623B1 Anti-fgf-8 antibodies against arthritis |
| 04/22/2009 | EP1424387B1 Method of extended culture for antigen-specific cytotoxic t lymphocytes |
| 04/22/2009 | EP1379873B1 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 04/22/2009 | EP1317419B1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 04/22/2009 | EP1299727B1 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 04/22/2009 | EP1214088B1 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 04/22/2009 | EP1200126B1 Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections |
| 04/22/2009 | EP1190101B1 Compositions and methods for preventing transepithelial transmission of hiv |
| 04/22/2009 | EP1181319B1 Chimeric dr4 antibodies and uses thereof |
| 04/22/2009 | EP1090039B1 Peptide composition as immunogen for the treatment of allergy |
| 04/22/2009 | EP1089757B1 Hla binding peptides and their uses |
| 04/22/2009 | EP1057889B1 Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same |
| 04/22/2009 | EP0882134B1 Methods and compositions for protective and therapeutic genetic immunization |
| 04/22/2009 | EP0882067B2 Methods of treating vascular disease with tnf antagonists |
| 04/22/2009 | EP0842948B1 ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME |
| 04/22/2009 | CN101415835A Compositions and methods for the analysis and treatment of AIDS wasting syndrome and immune cell dysfunction |
| 04/22/2009 | CN101415827A Methods for generating antigen-specific effector T cells |
| 04/22/2009 | CN101415820A Production of biologically active proteins |
| 04/22/2009 | CN101415819A Anti-IL-6 antibodies, compositions, methods and uses |
| 04/22/2009 | CN101415730A Compositions and methods of use for antibodies of c-Met |
| 04/22/2009 | CN101415729A Antibodies against amyloid-beta peptide |
| 04/22/2009 | CN101415728A Anti-IGF-1R antibodies and uses thereof |
| 04/22/2009 | CN101415439A Glp-1 agonists, compositions, methods and uses |
| 04/22/2009 | CN101415438A TOLL like receptor 3 antagonists, methods and uses |
| 04/22/2009 | CN101415437A Dry powder compositions and systems for poultry vaccination |
| 04/22/2009 | CN101415436A Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use |
| 04/22/2009 | CN101415431A A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same |
| 04/22/2009 | CN101415403A Solid oral form of a medicinal preparation and a method for the production thereof |
| 04/22/2009 | CN101412984A Streptococcus suis type 2 three-component subunit vaccine and use |
| 04/22/2009 | CN101412759A Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| 04/22/2009 | CN101412758A Anti-ErbB2 antibodies |
| 04/22/2009 | CN101412754A Gastrin compositions and formulations, and methods of use and preparation |
| 04/22/2009 | CN101411876A Neurotoxic oligomers |
| 04/22/2009 | CN101411875A Preparation for preparing pig serum immunoglobulin long-acting dosage form |
| 04/22/2009 | CN101411874A Preparation for preparing dog serum immunoglobulin long-acting dosage form |
| 04/22/2009 | CN101411873A Dual inactivated vaccine lymph for ascites disease of cultivated flounder and preparation method |
| 04/22/2009 | CN101411872A Vaccine reagent kit for preventing carious tooth and method of use thereof |
| 04/22/2009 | CN100480388C HAb18Gedomab 1 monoclonal antibody and light and heavy chain variable area genes, coding polypeptide and use |
| 04/22/2009 | CN100480377C Infectious bursal disease virus VP2 gene expressed recombinant newcastle disease LaSota attenuated vaccine strain |
| 04/22/2009 | CN100480269C Anti-vegf antibodies |
| 04/22/2009 | CN100480260C Recombinant production of mixtures of antibodies |
| 04/22/2009 | CN100479859C Method for filtering out matters possible to restrain and/or activate target biological activity in aiming at phenomena of spatial allosterism of the target |
| 04/22/2009 | CN100479858C A recombined smallpox vaccine - SARS vaccine and preparation method thereof |
| 04/22/2009 | CN100479857C Anti-HIV medicine |
| 04/21/2009 | US7521549 Compounds |
| 04/21/2009 | US7521542 Humanized FcγRIIB-specific antibodies and methods of use thereof |
| 04/21/2009 | US7521532 Comprises nucleotide sequences coding transmembrane protein for diagnosis and treatment immunological and autoimmune diseases |
| 04/21/2009 | US7521258 Methods of detecting, measuring, and evaluating modulators of body weight in biological samples, and diagnostic, monitoring, and therapeutic uses thereof |
| 04/21/2009 | US7521229 replication-defective recombinant adenovirus comprising a heterologous nucleic acid sequence encoding an antigenic determinant of Plasmodium falciparum; ntigenic determinant comprises an immunogenic peptide of the circumsporozoite protein; viral vectors |
| 04/21/2009 | US7521218 use thereof for spreading living attenuated viruses; culture medium comprising a chicken serum and a culture support comprising inactivated 3T3 cells |
| 04/21/2009 | US7521206 Tumor necrosis factor (TNF); immunotherapy or diagnosis of TNF-related diseases such as cancer; nucleic acids, host cells, vectors |
| 04/21/2009 | US7521177 Contacting the sample with a flavivirus antigen,produced by expressing a transcriptional unit encoding a Japanese encephalitis virus (JEV) signal sequence and an immunogenic flavivirus antigen of a flavivirus; detecting an increase in antigen/antibody complex formation |
| 04/21/2009 | US7521062 Thiosemicarbazones as anti-virals and immunopotentiators |
| 04/21/2009 | US7521060 Pathogen for bacterial poultry disease |
| 04/21/2009 | US7521059 Low cost; includes killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior to killing |
| 04/21/2009 | US7521058 Nucleotide sequences coding viral protein for use in vaccinations and veterinary medicine |
| 04/21/2009 | US7521057 Lamprey GnRH-III polypeptides and methods of making thereof |
| 04/21/2009 | US7521056 Fusion propteins; homogeneous purity, and unaltered affinity, and can be produced in high yields without the requirement of extensive purification; stable in serum to allow in vivo applications |
| 04/21/2009 | US7521055 Detecting variant allele of human ferroportin1 gene and evaluating DNA sequence; administering inhibitor of Ferroportin1 iron transport function; oxidative damage in mammals, iron deficiency, hemochromatosis, anemia, and blood disorders; replication; administering polypeptide, immune response |
| 04/21/2009 | US7521053 Angiopoietin-2 specific binding agents |
| 04/21/2009 | US7521052 Administering an effective amount of an anti-IL-6 receptor antibody (anti-IL-6R antibody) and an effective amount of methotrexate (MTX) for therapy of rheumatoid arthritis |
| 04/21/2009 | US7521051 agonists and/or antagonists of PD-1 (Programmed Death 1) thereby modulate immune responses; treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer |
| 04/21/2009 | US7521049 Administering fusion proteins, immunoglobulins, and multimeric proteins; pharmacokinetics; age-related macular degeneration and diabetic retinopathy |
| 04/21/2009 | US7521048 TRAIL receptor-2 polypeptides and antibodies |
| 04/21/2009 | US7521046 Antibody immunization therapy for treatment of atherosclerosis |
| 04/21/2009 | US7521045 Methods of inhibiting metastasis |
| 04/21/2009 | US7521043 Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines |
| 04/21/2009 | US7521040 Immunotherapy for humans |
| 04/21/2009 | CA2338358C Compounds and compositions for delivering active agents |
| 04/21/2009 | CA2231603C Chicken interleukin-15 and uses thereof |
| 04/21/2009 | CA2193641C 66 kda antigen from borrelia |
| 04/21/2009 | CA2182949C Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/21/2009 | CA2115927C Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus |
| 04/21/2009 | CA1341594C Synthetic peptides and mixtures therof for detecting hiv antibodies |
| 04/16/2009 | WO2009049228A2 Compositions and methods for assessing disorders |
| 04/16/2009 | WO2009049184A2 Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
| 04/16/2009 | WO2009049138A1 Cytomegalovirus vaccines and methods of production |
| 04/16/2009 | WO2009049097A1 Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis |
| 04/16/2009 | WO2009049013A2 Cholera vaccines |
| 04/16/2009 | WO2009048980A2 Emp2 antibodies and their therapeutic uses |